AAP
39
7
PM
54
-2
LUV
48
3
VRSK
82
-2
LRCX
49
-3
DAL
85
2
NI
73
3
JCI
63
2
STI
12
-5
NUE
62
-2
WYNN
30
2
AMAT
49
-3
PWR
72
-2
JPM
69
2
CNP
46
-4
PBI
68
3
DE
40
4
COST
63
-4
ADSK
75
3
MOS
48
2
AAP
39
7
PM
54
-2
LUV
48
3
VRSK
82
-2
LRCX
49
-3
DAL
85
2
NI
73
3
JCI
63
2
STI
12
-5
NUE
62
-2
WYNN
30
2
AMAT
49
-3
PWR
72
-2
JPM
69
2
CNP
46
-4
PBI
68
3
DE
40
4
COST
63
-4
ADSK
75
3
MOS
48
2
Financhill
Back

Keros Therapeutics Quote, Financials, Valuation and Earnings

U.S. Government Report Alert Tuesday

Discover the Secret Loophole
Buy
80

KROS
Keros Therapeutics

Last Price:
64.84
Seasonality Move:
23.73%

7 Day Trial

ALL ACCESS PASS

$ 7

Trump's IRS Hands Massive 'Victory Gift' To 401K Owners

Shield your IRA, 401(k) and pension savings from this coming anti-Trump backlash.

Keros Therapeutics Price Quote

$64.84
-3.31 (-4.86%)
(Updated: November 12, 2024 at 5:55 PM ET)

Keros Therapeutics Key Stats

Buy
80
Keros Therapeutics (KROS) is a Buy
Day range:
$67.89 - $70.26
52-week range:
$27.31 - $73.00
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
3,651.24
P/B ratio:
5.18%
Volume:
422.5K
Avg. volume:
338.6K
1-year change:
130.47%
Market cap:
$2.8B
Revenue:
$151K
EPS:
$-5.21

How Much Does Keros Therapeutics Make?

Is Keros Therapeutics Growing As A Company?

  • What Is Keros Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 47.5%
  • What Is Keros Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Keros Therapeutics Stock Price Performance

What Is Keros Therapeutics 52-Week High & Low?

Keros Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Keros Therapeutics?

Is Keros Therapeutics Cash Flow Positive?

  • What Is KROS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$140.3M
  • What Is Keros Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $385.5M
  • What Is Keros Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$2.2M

Keros Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    KROS return on invested capital is -44.6%
  • What Is Keros Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -40.96%
  • What Is KROS Return On Equity?
    ROE is a measure of profitability and is -44.6%

Keros Therapeutics Earnings Date & Stock Price

Keros Therapeutics Competitors

  • Who Are Keros Therapeutics's Competitors?
    Below is a list of companies who compete with Keros Therapeutics or are related in some way:
    • Eli Lilly and Co (LLY)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)
    • Regeneron Pharmaceuticals Inc (REGN)
    • Scholar Rock Holding Corp (SRRK)

Keros Therapeutics Dividend Yield

Keros Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -10.52%
Revenue: 4750% 0%

Analyst Recommendations

Buy Recommendations: 11
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 90.69
Upside from Last Price: 33.08%

Major Shareholders

  • How many KROS shares are owned by institutional investors?
    50.1M KROS shares are owned by institutional investors
  • How many KROS shares are owned by insiders?
    372.4K KROS shares are owned by insiders